ATIONAL JOURNAL OF MOLECULAR MEDICINE 48: 197,Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathwayJIEBIN XIE1,2, YUESHAN PANG3 and XIAOTING WUDepartment of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041; 2 Division of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Health-related College; 3 Department of Geriatrics, The Second Clinical Healthcare College of North Sichuan Healthcare College, Nanchong Central Hospital, Nanchong, Sichuan 637000, P.R. China Received February 7, 2021; Accepted June 11, 2021 DOI: ten.3892/ijmm.2021.Abstract. The development of novel approaches for the treat ment of gastric cancer is of utmost significance. Taxifolin (Tax) has been reported to possess biological activities against a variety of types of cancer. The objective on the present study was to examine the effects of Tax on gastric cancer and to explore its potential mechanisms of action. For this goal, AGS and NCIN87 cells, at the same time as BALB/c mice with gastric cancer cellderived tumors were treated with Tax. Cell Counting Kit8 and colony formation assays have been performed to detect cell viability and proliferation, respectively. Woundhealing and Transwell assays were also carried out to establish the cell migratory and invasive skills, respectively. Western blot analysis was performed to establish protein expression in vitro and in vivo. The outcomes SIRT2 drug revealed that Tax drastically inhibited the viability, proliferation, migration and invasion of gastric cancer cells by way of the aryl hydrocarbon receptor (AhR)/cytochrome P450 1A1 (CYP1A1) signaling pathway. SB203580, an AhR agonist, partly abolished the inhibitory effects of Tax on gastric cancer cell viability, proliferation, migration and invasion. In addition, Tax also suppressed tumor development in vivo. Collectively, the present study demonstrated that Tax considerably suppressed the tumor traits of gastric cancer. Tax may possibly thus prove to become a prospective PARP Formulation therapeutic technique for gastric cancer. Introduction Gastric cancer is definitely the fifth most typical malignancy and the third most common reason for cancerrelated mortality world wide, with more than 1 million estimated new circumstances annually and 784,000 deaths globally in 2018, prompting the World HealthCorrespondence to: Professor Xiaoting Wu, Division ofGastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu, Sichuan 610041, P.R. China E-mail: wuxiaotingwxt@126 receptor, cytochrome P450 1AOrganization to declare it a public health concern (1,two). Gastric cancer is a multistep and multifactorial illness. The efficacy of gastric cancer remedy is dependent on the stage with the tumor. Patients with earlystage gastric cancer, who acquire radical surgery, have a favorable 5year survival rate; even so, the majority of patients are diagnosed at an sophisticated stage as a result of the inability of early detection, and also the 5year survival price of those patients is normally poor (3). Therefore, a novel therapeutic agent, at the same time as an enhanced understanding in the molecular mechanisms underlying gastric cancer, are urgently necessary in order to boost patient prognosis as well as the survival price. Taxifolin (Tax), also referred to as dihydroquercetin (3,5,7,3,4pentahydroxy flavanone), is really a flavonoid naturally occurring in milk thistle, onion, Douglas fir bark and French maritime pine bark, which has been reported to possess several biological activities in t